AbbVie Inc. (ABBV)
172.99
1.31 (0.76%)
At close: Apr 17, 2025, 3:59 PM
173.81
0.48%
After-hours: Apr 17, 2025, 08:00 PM EDT
AbbVie Revenue Breakdown
| Period Ending | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Botox Cosmetic Revenue | 671M | 633M | 718M | 620M | 685M | 659M | 642M | 637M | 695M | 641M | 626M | 545M | 584M | 477M | 493M | 393M | 226M | 559M | 60M | 695M | 780M | 790M | -58M | 839M | 108M | 103M | 100M | 94M | 81M | 80M | 78M | 74M | 73M | 68M | 62M | 61M | 55M | 53M | 56M | 56M | 56M | 52M | 88M | 46M | 44M | 277M |
| Botox Cosmetic Revenue Growth | +6.00% | -11.84% | +15.81% | -9.49% | +3.95% | +2.65% | +0.78% | -8.35% | +8.42% | +2.40% | +14.86% | -6.68% | +22.43% | -3.25% | +25.45% | +73.89% | -59.57% | +831.67% | -91.37% | -10.90% | -1.27% | -1462.07% | -106.91% | +676.85% | +4.85% | +3.00% | +6.38% | +16.05% | +1.25% | +2.56% | +5.41% | +1.37% | +7.35% | +9.68% | +1.64% | +10.91% | +3.77% | -5.36% | 0.00% | 0.00% | +7.69% | -40.91% | +91.30% | +4.55% | -84.12% | n/a |
| Juvederm Collection Revenue | 258M | 297M | 334M | 321M | 368M | 355M | 322M | 352M | 344M | 410M | 432M | 354M | 428M | 321M | 331M | 274M | 113M | 1.23B | n/a | 1.26B | 1.1B | 1.02B | n/a | 972M | 5.18B | 4.71B | 4.89B | 4.7B | 4.72B | 4.12B | 4.29B | 4.06B | 4.15B | 3.58B | 3.72B | 3.65B | 3.54B | 3.11B | 3.36B | 3.25B | 393M | 380M | 671M | 323M | 395M | n/a |
| Juvederm Collection Revenue Growth | -13.13% | -11.08% | +4.05% | -12.77% | +3.66% | +10.25% | -8.52% | +2.33% | -16.10% | -5.09% | +22.03% | -17.29% | +33.33% | -3.02% | +20.80% | +142.48% | -90.83% | n/a | n/a | +14.38% | +7.53% | n/a | n/a | -81.25% | +10.11% | -3.74% | +4.06% | -0.32% | +14.52% | -4.05% | +5.71% | -2.15% | +15.99% | -3.77% | +1.92% | +3.11% | +13.69% | -7.49% | +3.32% | +728.24% | +3.42% | -43.37% | +107.74% | -18.23% | n/a | n/a |
| Other Aesthetics Revenue | 310M | 319M | 319M | 298M | 331M | 286M | 323M | 312M | 332M | 323M | 349M | 352M | 422M | 343M | 318M | 300M | 142M | 317M | n/a | 221M | 169M | 151M | n/a | 96M | 850M | 762M | 708M | 688M | 626M | 551M | 511M | 501M | 439M | 381M | 343M | 304M | 107M | 303M | 486M | 370M | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Aesthetics Revenue Growth | -2.82% | 0.00% | +7.05% | -9.97% | +15.73% | -11.46% | +3.53% | -6.02% | +2.79% | -7.45% | -0.85% | -16.59% | +23.03% | +7.86% | +6.00% | +111.27% | -55.21% | n/a | n/a | +30.77% | +11.92% | n/a | n/a | -88.71% | +11.55% | +7.63% | +2.91% | +9.90% | +13.61% | +7.83% | +2.00% | +14.12% | +15.22% | +11.08% | +12.83% | +184.11% | -64.69% | -37.65% | +31.35% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Alphagan/Combigan Revenue | 62M | 59M | 66M | 70M | 65M | 71M | 74M | 73M | 92M | 107M | 141M | 128M | 142M | 118M | 134M | 123M | 69M | 4.7B | n/a | 4.94B | 4.87B | 4.45B | n/a | 5.12B | 151M | 201M | 231M | 181M | 289M | 297M | 289M | 342M | 309M | 277M | 302M | 310M | 308M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Alphagan/Combigan Revenue Growth | +5.08% | -10.61% | -5.71% | +7.69% | -8.45% | -4.05% | +1.37% | -20.65% | -14.02% | -24.11% | +10.16% | -9.86% | +20.34% | -11.94% | +8.94% | +78.26% | -98.53% | n/a | n/a | +1.36% | +9.54% | n/a | n/a | +3293.38% | -24.88% | -12.99% | +27.62% | -37.37% | -2.69% | +2.77% | -15.50% | +10.68% | +11.55% | -8.28% | -2.58% | +0.65% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Lumigan/Ganfort Revenue | 116M | 91M | 92M | 91M | 119M | 130M | 123M | 121M | 130M | 140M | 149M | 138M | 149M | 143M | 153M | 149M | 76M | 86M | n/a | 91M | 48M | 111M | n/a | 106M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Lumigan/Ganfort Revenue Growth | +27.47% | -1.09% | +1.10% | -23.53% | -8.46% | +5.69% | +1.65% | -6.92% | -7.14% | -6.04% | +7.97% | -7.38% | +4.20% | -6.54% | +2.68% | +96.05% | -11.63% | n/a | n/a | +89.58% | -56.76% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Eye Care Revenue | 207M | 200M | 181M | 207M | 215M | 200M | 283M | 287M | 327M | 278M | 306M | 286M | 301M | 276M | 296M | 269M | 128M | 300M | n/a | 117M | 115M | 114M | n/a | 25M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Eye Care Revenue Growth | +3.50% | +10.50% | -12.56% | -3.72% | +7.50% | -29.33% | -1.39% | -12.23% | +17.63% | -9.15% | +6.99% | -4.98% | +9.06% | -6.76% | +10.04% | +110.16% | -57.33% | n/a | n/a | +1.74% | +0.88% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Ozurdex Revenue | 119M | 131M | 118M | 120M | 119M | 115M | 110M | 142M | 168M | 246M | 364M | 319M | 327M | 280M | 344M | 299M | 144M | 124M | n/a | 83M | 254M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Ozurdex Revenue Growth | -9.16% | +11.02% | -1.67% | +0.84% | +3.48% | +4.55% | -22.54% | -15.48% | -31.71% | -32.42% | +14.11% | -2.45% | +16.79% | -18.60% | +15.05% | +107.64% | +16.13% | n/a | n/a | -67.32% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Restasis Revenue | 21M | 57M | 128M | 117M | 99M | 92M | 1.11B | 1.14B | 1.15B | 1.17B | 1.39B | 1.37B | 1.38B | 1.27B | 2.66B | 1.37B | 1.29B | 105M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Restasis Revenue Growth | -63.16% | -55.47% | +9.40% | +18.18% | +7.61% | -91.75% | -1.76% | -0.87% | -2.39% | -15.31% | +0.80% | -0.51% | +8.91% | -52.26% | +93.87% | +6.37% | +1126.67% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Imbruvica Revenue | 828M | 838M | 903M | 908M | 907M | 878M | 516M | 515M | 505M | 473M | 488M | 492M | 435M | 405M | 682M | 352M | 303M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Imbruvica Revenue Growth | -1.19% | -7.20% | -0.55% | +0.11% | +3.30% | +70.16% | +0.19% | +1.98% | +6.77% | -3.07% | -0.81% | +13.10% | +7.41% | -40.62% | +93.75% | +16.17% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| VENCLEXTA Revenue | 677M | 614M | 589M | 590M | 571M | 538M | 5.58B | 5.56B | 5.36B | 4.74B | 5.33B | 5.42B | 5.07B | 4.87B | 9.86B | 5.14B | 4.84B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| VENCLEXTA Revenue Growth | +10.26% | +4.24% | -0.17% | +3.33% | +6.13% | -90.36% | +0.36% | +3.65% | +13.24% | -11.21% | -1.68% | +7.04% | +4.13% | -50.61% | +91.73% | +6.26% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| H U M I R A Revenue | 2.23B | 2.27B | 3.3B | 3.55B | 4.01B | 3.54B | 770M | 695M | 592M | 465M | 517M | 453M | 378M | 303M | 367M | 215M | 149M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| H U M I R A Revenue Growth | -1.89% | -31.30% | -6.85% | -11.59% | +13.30% | +359.87% | +10.79% | +17.40% | +27.31% | -10.06% | +14.13% | +19.84% | +24.75% | -17.44% | +70.70% | +44.30% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| RINVOQ Revenue | 1.61B | 1.09B | 1.25B | 1.11B | 918M | 686M | 1.58B | 1.4B | 1.25B | 940M | 895M | 796M | 674M | 574M | 825M | 435M | 330M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| RINVOQ Revenue Growth | +47.67% | -12.91% | +13.06% | +20.92% | +33.82% | -56.47% | +12.81% | +11.58% | +33.19% | +5.03% | +12.44% | +18.10% | +17.42% | -30.42% | +89.66% | +31.82% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| SKYRIZI Revenue | 3.21B | 2.01B | 2.39B | 2.13B | 1.88B | 1.36B | 728M | 699M | 678M | 614M | 671M | 645M | 603M | 532M | 567M | 523M | 297M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| SKYRIZI Revenue Growth | +59.61% | -16.12% | +12.61% | +12.90% | +38.46% | +86.81% | +4.15% | +3.10% | +10.42% | -8.49% | +4.03% | +6.97% | +13.35% | -6.17% | +8.41% | +76.09% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Botox Therapeutic Revenue | 848M | 748M | 776M | 748M | 748M | 719M | 107M | 110M | 120M | 121M | 128M | 127M | 127M | 129M | 253M | 123M | 118M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Botox Therapeutic Revenue Growth | +13.37% | -3.61% | +3.74% | 0.00% | +4.03% | +571.96% | -2.73% | -8.33% | -0.83% | -5.47% | +0.79% | 0.00% | -1.55% | -49.01% | +105.69% | +4.24% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Duodopa Revenue | 111M | 115M | 115M | 118M | 117M | 118M | 61M | 87M | 150M | 177M | 183M | 171M | 171M | 160M | 227M | 207M | 105M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Duodopa Revenue Growth | -3.48% | 0.00% | -2.54% | +0.85% | -0.85% | +93.44% | -29.89% | -42.00% | -15.25% | -3.28% | +7.02% | 0.00% | +6.88% | -29.52% | +9.66% | +97.14% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Neuroscience Revenue | 84M | 74M | 66M | 61M | 70M | 79M | 269M | 271M | 255M | 240M | 287M | 261M | 268M | 222M | 286M | 248M | 133M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Neuroscience Revenue Growth | +13.51% | +12.12% | +8.20% | -12.86% | -11.39% | -70.63% | -0.74% | +6.27% | +6.25% | -16.38% | +9.96% | -2.61% | +20.72% | -22.38% | +15.32% | +86.47% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Qulipta Revenue | 176M | 131M | 180M | 132M | 96M | 152M | 380M | 383M | 398M | 380M | 427M | 426M | 442M | 415M | 1.04B | 414M | 376M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Qulipta Revenue Growth | +34.35% | -27.22% | +36.36% | +37.50% | -36.84% | -60.00% | -0.78% | -3.77% | +4.74% | -11.01% | +0.23% | -3.62% | +6.51% | -60.10% | +151.21% | +10.11% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Ubrelvy Revenue | 269M | 203M | 234M | 233M | 196M | 561M | 992M | 925M | 1.01B | 1.21B | 594M | 547M | 640M | 892M | 1.4B | 829M | 590M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Ubrelvy Revenue Growth | +32.51% | -13.25% | +0.43% | +18.88% | -65.06% | -43.45% | +7.24% | -8.33% | -16.68% | +103.87% | +8.59% | -14.53% | -28.25% | -36.24% | +68.76% | +40.51% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Vraylar Revenue | 875M | 694M | 789M | 751M | 658M | 259M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Vraylar Revenue Growth | +26.08% | -12.04% | +5.06% | +14.13% | +154.05% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Linzess/Constella Revenue | 234M | 266M | 283M | 288M | 278M | 364M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Linzess/Constella Revenue Growth | -12.03% | -6.01% | -1.74% | +3.60% | -23.63% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| MAVYRET Revenue | 302M | 349M | 309M | 370M | 387M | 691M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| MAVYRET Revenue Growth | -13.47% | +12.94% | -16.49% | -4.39% | -43.99% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Products Revenue | 726M | 744M | 821M | 782M | 741M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Products Revenue Growth | -2.42% | -9.38% | +4.99% | +5.53% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Australia Revenue | 472M | 508M | 533M | 527M | 359M | 350M | 410M | 355M | 4B | 3.27B | 439M |
| Australia Revenue Growth | -7.09% | -4.69% | +1.14% | +46.80% | +2.57% | -14.63% | +15.49% | -91.13% | +22.28% | +645.33% | n/a |
| Brazil Revenue | 439M | 430M | 368M | 406M | 813M | 730M | 659M | 624M | n/a | n/a | 538M |
| Brazil Revenue Growth | +2.09% | +16.85% | -9.36% | -50.06% | +11.37% | +10.77% | +5.61% | n/a | n/a | n/a | n/a |
| Canada Revenue | 1.08B | 1.16B | 1.4B | 1.16B | 695M | 783M | 730M | 713M | n/a | n/a | 540M |
| Canada Revenue Growth | -7.16% | -17.04% | +20.53% | +66.76% | -11.24% | +7.26% | +2.38% | n/a | n/a | n/a | n/a |
| China Revenue | 950M | 912M | 857M | 471M | 909M | 1.29B | 1.16B | 1.1B | n/a | n/a | 911M |
| China Revenue Growth | +4.17% | +6.42% | +81.95% | -48.18% | -29.64% | +11.67% | +4.80% | n/a | n/a | n/a | n/a |
| France Revenue | 780M | 787M | 936M | 797M | 372M | 652M | 475M | 523M | n/a | n/a | 404M |
| France Revenue Growth | -0.89% | -15.92% | +17.44% | +114.25% | -42.94% | +37.26% | -9.18% | n/a | n/a | n/a | n/a |
| Germany Revenue | 1.27B | 1.34B | 1.22B | 1.05B | 1.21B | 1.59B | 764M | 770M | n/a | n/a | 625M |
| Germany Revenue Growth | -5.52% | +9.57% | +16.59% | -13.38% | -23.88% | +108.25% | -0.78% | n/a | n/a | n/a | n/a |
| Italy Revenue | 484M | 444M | 506M | 379M | 3.99B | 4.01B | 4.08B | 3.88B | n/a | n/a | 3.15B |
| Italy Revenue Growth | +9.01% | -12.25% | +33.51% | -90.51% | -0.50% | -1.64% | +5.02% | n/a | n/a | n/a | n/a |
| Japan Revenue | 1.01B | 956M | 1.09B | 1.2B | 472M | 611M | 521M | 589M | n/a | n/a | 543M |
| Japan Revenue Growth | +5.44% | -12.29% | -9.02% | +153.81% | -22.75% | +17.27% | -11.54% | n/a | n/a | n/a | n/a |
| Other Countries Revenue | 5.04B | 4.84B | 4.76B | 3.98B | n/a | n/a | 18.25B | 15.95B | n/a | n/a | 10.18B |
| Other Countries Revenue Growth | +4.24% | +1.60% | +19.71% | n/a | n/a | n/a | +14.45% | n/a | n/a | n/a | n/a |
| Spain Revenue | 501M | 506M | 519M | 453M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Spain Revenue Growth | -0.99% | -2.50% | +14.57% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue | 41.88B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 3.85B | 4.21B | 3.34B | 3.3B | 3.61B | 3.37B | 3.27B | 3.04B | 3.42B | 3.3B | 5.41B | 3.13B | 3.26B | 3.08B | 3.16B | 2.84B | 3.23B | 2.85B | 3.53B | 1.7B | 1.95B | 1.66B | 1.65B | 1.68B | 1.93B | 1.92B | 1.76B | 1.79B | 1.95B | 1.45B | 1.5B | 1.37B | 1.65B | 1.38B | 1.47B | 1.35B | 1.74B | 1.47B | 1.7B | 1.47B |
| Selling, General, and Administrative Revenue Growth | -8.32% | +25.82% | +1.27% | -8.49% | +6.94% | +3.18% | +7.54% | -11.06% | +3.42% | -38.95% | +73.07% | -4.08% | +5.74% | -2.56% | +11.33% | -12.04% | +13.53% | -19.31% | +108.08% | -13.12% | +17.74% | +0.18% | -1.55% | -12.91% | +0.52% | +9.03% | -1.73% | -8.20% | +34.37% | -3.46% | +9.94% | -17.24% | +19.70% | -5.80% | +8.19% | -21.99% | +17.84% | -13.45% | +15.61% | n/a |
| Research and Development Revenue | 6.77B | 2.13B | 1.92B | 1.94B | 1.92B | 1.72B | 1.73B | 2.29B | 1.79B | 1.61B | 1.61B | 1.5B | 1.83B | 1.67B | 1.8B | 1.78B | 1.89B | 1.71B | 1.58B | 1.38B | 1.54B | 2.29B | 1.29B | 1.29B | 6.5B | 1.27B | 1.32B | 1.24B | 1.4B | 1.22B | 1.22B | 1.14B | 1.19B | 1.11B | 1.12B | 946M | 1.07B | 1.42B | 981M | 811M |
| Research and Development Revenue Growth | +218.03% | +11.11% | -1.13% | +0.94% | +11.49% | -0.58% | -24.39% | +28.04% | +10.90% | +0.31% | +7.48% | -18.06% | +9.21% | -7.16% | +1.12% | -5.71% | +10.79% | +7.84% | +14.72% | -10.57% | -32.52% | +76.99% | +0.16% | -80.15% | +412.22% | -4.08% | +6.27% | -11.27% | +14.73% | -0.08% | +7.75% | -4.62% | +7.59% | -1.60% | +18.82% | -12.00% | -24.19% | +44.55% | +20.96% | n/a |